8月1日，就公司在研药物GLP-1和GIP受体双重激动剂BGM0504注射液与华润三九（000999）在中国大 陆地区(不包含香港、澳门及台湾地区)达成研发、注册、生产及商业化合作，博瑞医药回复第一财经记 者称，该项目合作并未发生专利权属的变更，博瑞医药及关联公司仍是BGM0504注射液项目现有专利 的专利权人，与华润三九的合作也不影响公司积极探索海外市场。(第一财经) ...

博瑞医药董事长袁建栋表示："BGM0504注射液是一项重大创新成果。公司期待借助华润三九强大的注 册申报、市场覆盖和商业化能力，高效转化创新成果，让BGM0504注射液早日惠及中国患者。同时， 双方还将在临床研究策略上进行紧密协作，共同设计探索前沿的临床试验方案，为未来的学术推广奠定 坚实基础。这种优势互补、资源共享的合作模式，将有望推动实现双方共赢，并最终造福患者。" 华润三九董事长邱华伟表示："此次合作是双方优势的深度融合。华润三九的产业资源、商业化能力与 博瑞医药的研发优势、创新实力形成互补，既有利于加速BGM0504注射液的研发进程，也有利于推动 创新药管线的商业化落地，实现创新成果向临床价值的高效转化，达成创新驱动与商业拓展的协同发 展。双方将聚焦减重和降糖这两大核心功效构建品牌优势，同时积极拓展其他适应症市场，让这款创新 药的价值得到更充分的释放。" 当前，2型糖尿病（T2DM）和肥胖症已成为全球及中国面临的重大公共卫生挑战。国际糖尿病联盟 （IDF）第11版《世界糖尿病地图》显示，2024年我国糖尿病患者约1.48亿人。其中，T2DM患者在糖 尿病患者群体中占绝大多数，其患病率持续攀升；此外，超 ...

Group 1 - The core viewpoint of the news is the collaboration between China Resources Sanjiu (华润三九) and Borui Pharmaceutical (博瑞医药) to develop the BGM0504 injection, aimed at addressing the rising public health challenges of Type 2 Diabetes Mellitus (T2DM) and obesity in China [1][2] - The BGM0504 injection is a dual agonist of GLP-1 and GIP receptors, classified as an innovative peptide drug, and is currently in the critical phase of Phase III clinical trials [2] - The partnership aims to leverage the strengths of both companies, combining China Resources Sanjiu's commercial capabilities with Borui Pharmaceutical's research advantages to accelerate the development and commercialization of BGM0504 in the Chinese market [2] Group 2 - The collaboration is expected to enhance the brand's competitive edge by focusing on weight loss and blood sugar reduction, while also exploring other potential indications for the drug [2] - Both companies emphasize the importance of addressing unmet clinical needs and aim to efficiently translate innovative results into clinical value for patients [2] - The cooperative model of resource sharing and complementary advantages is anticipated to lead to mutual benefits for both companies and ultimately benefit patients [2]

Group 1 - Yabont Chemical signed a 10-year supply strategic agreement with Jiangsu Hengrui Medicine to enhance collaboration in the pharmaceutical supply chain, effective from August 1, 2025 [1] - Wei Hua New Materials plans to acquire controlling interest in Jiangsu Heyutai Chemical to extend its product chain and improve competitiveness, currently in the planning stage [2] - Fujirey received a government subsidy of 2.0074 million yuan, expected to positively impact profits in 2025 [4] Group 2 - Hangzhou Garden won the land use rights for a plot in Yuhang District for 130 million yuan, planning to build a smart ecological design R&D headquarters with a total investment of no more than 450 million yuan [5] - Baotai's clinical trial for BAT5906, a recombinant anti-VEGF monoclonal antibody, received approval for new indications, aiming to accelerate commercialization [6] - Weisheng Information won multiple projects with a total bid amount of 110 million yuan, including significant contracts with Southern Power Grid and State Grid [8] Group 3 - Dong'an Power reported a 27.37% year-on-year increase in engine sales for July, totaling 34,500 units [13] - Hanma Technology's truck sales reached 956 units in July, marking a 42.69% year-on-year increase [14] - Jiangsu Bank's executives received regulatory approval for their positions, effective immediately [15] Group 4 - Chip Origin expects Q2 revenue of 584 million yuan, a 49.90% increase quarter-on-quarter, with significant growth in intellectual property licensing fees [24] - Dream Network Technology plans to establish a high-end equipment industry investment fund with a target fundraising of 2 billion yuan [26] - Hefei Urban Construction and China Real Estate Development won land use rights for a residential plot in Hefei for 980 million yuan [28] Group 5 - Lu Kang Pharmaceutical's subsidiary received a drug registration certificate for a new medication for erectile dysfunction [28] - Lifan Pharmaceutical's Mesalazine enteric-coated tablets received a drug registration certificate for treating ulcerative colitis [29] - Yahu Pharmaceutical's APL-1401 clinical trial for ulcerative colitis showed positive preliminary results [30]

天眼查商业履历信息显示，博瑞生物医药(苏州)股份有限公司，成立于2001年，位于苏州市，是一家以 从事医药制造业为主的企业。企业注册资本42246.505万人民币，实缴资本22062.4827万人民币。公司法 定代表人为袁建栋。 通过天眼查大数据分析，博瑞生物医药(苏州)股份有限公司共对外投资了38家企业，参与招投标项目49 次，知识产权方面有商标信息121条，专利信息178条，此外企业还拥有行政许可37个。 来源：金融界 金融界消息 截至2025年8月1日收盘，博瑞医药（688166）报收于99.25元，上涨1.5%，换手率3.02%， 成交量12.75万手，成交金额12.69亿元。 资金流向方面，今日主力资金净流入2625.10万元，占比成交额2.07%。其中，超大单净流入2555.99万 元、占成交额2.01%，大单净流入69.11万元、占成交额0.05%，中单净流出流出5191.61万元、占成交额 4.09%，小单净流入2566.51万元、占成交额2.02%。 博瑞医药最新一期业绩显示，截至2025一季报，公司营业总收入2.49亿元、同比减少26.81%，归属净利 润1295.98万元，同比减少79. ...

《合作研发协议》明确了博瑞医药将与华润三九在合作区域内就BGM0504注射液共同进行后续开发， 共同推进商业化。与此同时博瑞医药将作为BGM0504注射液在合作区域内的唯一上市许可持有人，承 担法律法规规定的应由MAH承担的全部义务和责任。 当前，2型糖尿病（T2DM）和肥胖症已成为全球及中国面临的重大公共卫生挑战。国际糖尿病联盟 （IDF）第11版《世界糖尿病地图》显示，2024年我国糖尿病患者约1.48亿人。其中，T2DM患者在糖 尿病患者群体中占绝大多数，其患病率持续攀升；此外，超重和肥胖作为慢性疾病中的独立病种及多种 慢性疾病的重要致病因素，在我国人群中的患病率呈持续上升趋势，亟需更多创新疗法以满足日益增长 的临床需求。 BGM0504注射液是一款GLP-1（胰高血糖素样肽1）和GIP（葡萄糖依赖性促胰岛素多肽）受体双重激 动剂，属于化学药品1类创新药，拟用于治疗T2DM和肥胖症。其独特的机制有望克服现有药物的部分 不足，为患者提供更有效、更安全、更便捷的治疗选择。目前，该药物已进展至III期临床试验关键阶 段。此次与华润三九的合作将有利于加速BGM0504注射液在中国市场的研发与上市步伐。 2025 ...

目前BGM0504注射液尚处于研发阶段，后续尚需开展并完成Ⅲ期临床研究，并经国家药监局审评、审 批通过后方可生产上市。 博瑞医药(688166.SH)公告，公司及全资子公司博瑞制药(苏州)有限公司(简称"博瑞制药")、博瑞新创生 物医药科技(无锡)有限公司(该三家许可方统称为"博瑞医药及关联公司")与华润三九（000999）签署了 《合作研发协议》，就BGM0504注射液在中国大陆地区的研发、注册、生产及商业化达成合作，博瑞 医药及关联公司授予华润三九一项仅与博瑞医药及关联公司合作的可分许可的排他性合作开发实施许可 及一项可分许可的独占性商业化实施许可。 公告显示，BGM0504注射液是公司自主研发的GLP-1(胰高血糖素样肽1)和GIP(葡萄糖依赖性促胰岛素 多肽)受体双重激动剂，属于境内外均未上市化学药品1类创新药。BGM0504注射液可激动GIP和GLP-1 下游通路，产生控制血糖、减重和治疗非酒精性脂肪性肝炎(NASH)等生物学效应，展现多种代谢疾病 治疗潜力。 ...

证券代码：688166 证券简称：博瑞医药 公告编号：2025-053 博瑞生物医药（苏州）股份有限公司 关于与华润三九医药股份有限公司签署合作研发协 议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 博瑞生物医药（苏州）股份有限公司（以下简称"公司"或"博瑞医药"） 及全资子公司博瑞制药（苏州）有限公司（以下简称"博瑞制药"）、博瑞新创生 物医药科技（无锡）有限公司（该三家许可方统称为"博瑞医药及关联公司"） 与华润三九医药股份有限公司（以下简称"华润三九"）签署了《合作研发协议》， 就 BGM0504 注射液在中国大陆地区（不包含香港、澳门及台湾地区）的研发、 注册、生产及商业化达成合作，博瑞医药及关联公司授予华润三九一项仅与博瑞 医药及关联公司合作的可分许可的排他性合作开发实施许可及一项可分许可的 独占性商业化实施许可。 本协议的签署已履行了相应的内部审批程序，无需提交公司董事会及股 东大会审议。 协议中约定的里程碑付款需要满足一定的条件，最终里程碑付款金额尚 存在不确定性。BGM0504 注 ...

Core Viewpoint - The company, Borui Pharmaceutical, has signed a collaboration research agreement with China Resources Sanjiu for the development, registration, production, and commercialization of BGM0504 injection in mainland China [1] Group 1: Collaboration Agreement - Borui Pharmaceutical and its subsidiaries have granted China Resources Sanjiu exclusive collaboration development and commercialization licenses for BGM0504 injection [1] - The agreement allows for a sublicensable exclusive collaboration development implementation license and a sublicensable exclusive commercialization implementation license [1] Group 2: Product Details - BGM0504 injection is a dual agonist of GLP-1 and GIP, classified as a first-class innovative chemical drug that has not yet been marketed domestically or internationally [1] - The injection aims to control blood sugar, promote weight loss, and treat non-alcoholic steatohepatitis (NASH), showcasing potential for various metabolic disease treatments [1] Group 3: Development Status - BGM0504 injection is currently in the research phase and requires completion of Phase III clinical trials before it can be reviewed and approved by the National Medical Products Administration for production and market launch [1]

格隆汇8月1日丨博瑞医药（维权）(688166.SH)公布，公司及全资子公司博瑞制药(苏州)有限公司(以下 简称"博瑞制药")、博瑞新创生物医药科技(无锡)有限公司(该三家许可方统称为"博瑞医药及关联公司") 与华润三九医药股份有限公司(以下简称"华润三九")签署了《合作研发协议》，就BGM0504注射液在中 国大陆地区(不包含香港、澳门及台湾地区)的研发、注册、生产及商业化达成合作，博瑞医药及关联公 司授予华润三九一项仅与博瑞医药及关联公司合作的可分许可的排他性合作开发实施许可及一项可分许 可的独占性商业化实施许可。 ...